Table of contents


On 26 February 2019, orphan designation (EU/3/19/2138) was granted by the European Commission to Common Services Agency (National Health Services - Scotland), United Kingdom, for allogeneic anti-Epstein Barr virus cytotoxic lymphocytes expanded ex vivo for the treatment of post-transplant lymphoproliferative disorder.

Key facts

Active substance
Allogeneic anti-Epstein Barr virus cytotoxic T lymphocytes expanded ex vivo
Disease / condition
Treatment of post-transplant lymphoproliferative disorder
Date of first decision
EU designation number

Sponsor's contact details

Common Services Agency (National Health Services - Scotland)
Gyle Square 
1 South Gyle Crescent 
EH12 9EB 
United Kingdom
Tel. +44 (0)131 3145610

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating